Taspoglutide: Research, Dosing, and Where to Buy in 2026

What is Taspoglutide?

Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.

Taspoglutide Dosing Protocols

The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.

Where to Buy Taspoglutide in 2026

Side Effects and Safety

User Reviews

Research Efficacy Snapshot

Published efficacy percentages cited in PubMed trials and named-expert reports about Taspoglutide. Each line links to the original source.

• "Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has >90% homology with the endogenous GLP-1 while retaining equivalent potency." · Sturm-Pellanda C et al, 2015 PubMed
• "The geometric mean ratio (relative bioavailability) for the upper arm versus the abdomen was 1.41 (90% CI: 1.22-1.62) and for the thigh versus the abdomen was 1.13 (90% CI: 0.98-1.31)." · Sturm-Pellanda C et al, 2015 PubMed
• "Corresponding Cmax values for subcutaneous injections in the abdomen, upper arm, and thigh were 0.268, 0.382, and 0.341 ng/mL, respectively, and the geometric mean ratio for the upper arm versus the abdomen was 1.43 (90% CI: 1.24-1.64) and for the thigh versus the abdomen was 1.27 (90% CI: 1.10-1.46)." · Sturm-Pellanda C et al, 2015 PubMed
• "The geometric mean ratio for period 2 versus 1 was 0.44 (90% CI: 0.38-0.50) and for period 3 versus 1 was 0.32 (90% CI: 0.27-0.37)." · Sturm-Pellanda C et al, 2015 PubMed
• "The pharmacodynamic potency (41.7 pmol/l) produced 50% of maximum response of WT (-1.85 kg) from the responses of placebo (-1.33 kg)." · Li H et al, 2015 PubMed
• "The odds ratio for the composite endpoint among people randomized to taspoglutide was 0.94 (95% confidence interval 0.57-1.56), which was robust across multiple subgroups." · Seshasai S et al, 2015 PubMed
• "placebo (least square mean -1.35 and -1.40% vs." · Henry R et al, 2012 PubMed
• "-0.45%, respectively; P < 0.0001)." · Henry R et al, 2012 PubMed
• "A greater proportion of taspoglutide-treated patients reached HbA1c target 7% or less (69.8 and 76.1% vs." · Henry R et al, 2012 PubMed
• "Adverse events were generally mild to moderate; the most frequent adverse events with taspoglutide 10 mg, taspoglutide 20 mg, and placebo were nausea (35, 44, and 10%), vomiting (21, 24, and 2%), and injection site reactions (24, 24, and 5%)." · Henry R et al, 2012 PubMed

Taspoglutide Research Findings in Numbers

Quantitative results quoted verbatim from the indexed peer-reviewed studies and attributed clinical protocols below.

• The pharmacodynamic potency (41.7 pmol/l) produced 50% of maximum response of WT (-1.85 kg) from the responses of placebo (-1.33 kg). PMID 25997251
• Sixty subjects were randomized into the study (mean age, 45.5 years PMID 26412802
• and body mass index, 31.4 kg/m(2)). PMID 26412802
• A significant reduction in HbA1c was observed with taspoglutide 10 mg and 20 mg vs. PMID 22539590
• With taspoglutide 10 mg and 20 mg vs. PMID 22539590
• placebo, significantly greater reductions in fasting plasma glucose [-1.87 mmol/liter (-34 mg/dl) and -2.12 mmol/liter (-38 mg/dl) vs. PMID 22539590
• -0.57 mmol/liter (-10 mg/dl) PMID 22539590
• 0.0001), and significant weight loss (-0.64 kg and -1.04 kg vs. PMID 22539590

Research and Studies

8 PubMed-indexed papers reference Taspoglutide. Top 8 shown.

Legal Status

Frequently Asked Questions